PS-341 (Pyz-Phe-boroLeu) is the active ingredient in Bortezomib. PS-341 is a reversible, cell permeable, potent, and selective proteasome inhibitor (Ki=0.6 nM). It binds the catalytic site of the 26S proteasome with high affinity and specificity. Inhibits proliferation of a number of tumor cell lines (IC50=7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis.

Pyz–Phe–boroLeu, N–(2–pyrazine)carbonyl–L–phenylalanyl–L–leucyl boronic acid

>98% by HPLC.

Soluble in DMSO

White powder

Store at +4°C. Stable as supplied for up to 2 years when stored dessicated at +4°C. Store solutions at -20°C for up to 1 week.

Useful for as a potent, cell permeable proteasome inhibitor for drug discovery research.

1. Yi-He Ling et all. PS-341, a Novel Proteasome Inhibitor, Induces Bcl-2 Phosphorylation and Cleavage in Association with G2-M Phase Arrest and Apoptosis. Mol Cancer Ther. 2002; 1:841-849.
2. Adams J. Development of the Proteasome Inhibitor PS-341. The Oncologist 2002; 7:9-16.
. Dudek SA et al. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. J Virol. 2010 Sep;84:9439-51.

Protect from moisture. Avoid freeze/thaw cycles.

Ubiquitin Enzymes

Inhibitors/Activators